Epitopea Partners with Merck to Discover Cryptigen Tumor-Specific Antigens

Shots:

• Epitopea & Merck have entered into license & research collaboration agreement to discover Cryptigen tumor-specific antigens (TSAs) in an undisclosed solid tumor
• As per the deal, Epitopea will receive an undisclosed upfront & ~$300M in milestones per product in exchange for Merck receiving exclusive development & commercialization rights to the TSA products identified via Epitopea’s CryptoMap platform
• Cryptigen TSAs are shared, non-mutated antigens that are aberrantly expressed & derived from genomic regions previously acknowledged as non-coding or junk DNA

Ref: Epitopea | Image: Epitopea & Merck

Related News:- Merck Receives the EC’s Approval for Welireg (Belzutifan) for Von Hippel-Lindau (VHL) Disease-Associated Tumors and Previously Treated Renal Cell Carcinoma

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com